✨ Free AI Report
Evolus, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Evolus, Inc.
Company Research

Evolus, Inc.: Business Overview, Financials & Competitive Analysis

Evolus, Inc. scores 7/10 on the AskCyborg Cyborg Score (Solid). Analysts rate EOLS as "Strong Buy" with a 12-month price target of $20.5, representing 262% upside, driven by market expansion and product portfolio growth. Revenue grew 31.76% to $266.27 million in 2024, with improving unit economics and strong market share gains. However, the company posted net losses of -$50.42 million.

What is Evolus, Inc.'s industry? Evolus, Inc. (evolus.com) operates in Medical Aesthetics / Performance Beauty. AskCyborg classifies Evolus, Inc. under Medical Aesthetics / Performance Beauty in its company registry.

Evolus is a performance beauty company delivering aesthetic products in the cash-pay market, with flagship product Jeuveau, a proprietary botulinum toxin formulation for reducing frown lines, and Evolysse, a collectio...

7/ 10Solid

Cyborg Score thesis

Analysts rate EOLS as "Strong Buy" with a 12-month price target of $20.5, representing 262% upside, driven by market expansion...

Read the full analyst-debate transcript →
Industry Medical Aesthetics / Performance Beauty
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Evolus, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Evolus, Inc.

AskCyborg analysts argue the bull and bear cases for Evolus, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Evolus, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Evolus, Inc. Overview

Pro stress-test →

Evolus is a performance beauty company delivering aesthetic products in the cash-pay market, with flagship product Jeuveau, a proprietary botulinum toxin formulation for reducing frown lines, and Evolysse, a collection of injectable hyaluronic acid gels. Jeuveau has rapidly achieved approximately 12% U.S. neurotoxin market share by Q3 2024.

Strategic Profile

Pro stress-test →

Unlike diversified competitors, Evolus concentrates exclusively on high-growth aesthetics neurotoxin and filler markets, enabling tailored marketing and deeper relationships within the aesthetic community. The company has evolved the medical aesthetics business model by moving away from a reimbursement model and partnering with customers differently to provide greater value.

Competitive Landscape

Pro stress-test →

Evolus competes in the high-growth aesthetics neurotoxin and filler markets against larger diversified players with therapeutic portfolios. The company differentiates through focused expertise, proprietary formulations, and digital-first marketing targeting practitioners and younger demographics.

Industry Context

Evolus, Inc. operates in Medical Aesthetics / Performance Beauty.

Key facts

Founded: 2012 · Headquarters: Newport Beach, US · Revenue: $0.27B · Market cap: $0.7B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Evolus, Inc..

  • Jeuveau achieved 12% neurotoxin market share by Q3 2024 with fastest-growing trajectory for four consecutive years
  • Revenue grew 31.76% YoY to $266.27 million in 2024, demonstrating strong commercial traction
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025Commercial launch of Evolysse injectable hyaluronic acid gels collection
  • Q2 2025Reported positive topline results exceeding expectations with continued market share gains
  • +1 moreTrack every material event for Evolus, Inc. as it happens. Explore monitoring →
Get alerted when Evolus, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BotoxLeading botulinum toxin for aesthetic and therapeutic applications→DysportEstablished botulinum toxin competitor in aesthetics market→XeominBotulinum toxin alternative in aesthetics segment→

Compare Evolus, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Evolus, Inc. operates in Medical Aesthetics / Performance Beauty. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Aesthetics / Performance Beauty research →
NEW · MCP server

Ask your AI assistant about Evolus, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Evolus, Inc. and its top competitor on Cyborg Score”
“What did Evolus, Inc. do this quarter?”
“Is Evolus, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Evolus, Inc. do?+
Evolus is a performance beauty company delivering aesthetic products in the cash-pay market, with flagship product Jeuveau, a proprietary botulinum toxin formulation for reducing frown lines, and Evolysse, a collectio...
What is Evolus, Inc.'s Cyborg Score?+
Evolus, Inc. has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Evolus, Inc.'s main competitors?+
Named competitors include Botox, Dysport, Xeomin. The full competitive landscape is in the AskCyborg report.
How can I get the full Evolus, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Evolus, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Evolus, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Aesthetics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6AirSculpt Technologies